We all want the best for our furry friends. That’s why ZOM stock is surging higher on positive news from Zomedica Pharmaceuticals. Pfizer CEO Albert Bourla sold off millions in stock as the company’s share price peaked following the vaccine news President Donald Trump has stepped up a conflict with China over security and technology by issuing an order barring Americans from investing in companies that U.S. officials say are owned or controlled by the Chinese military. Stock markets are always unpredictable. You can lose money in split seconds or become a millionaire too. However, Jeff Brown views the stock market differently, and losing is not his portion. He be…
Animal lovers, unite! Zomedica Pharmaceuticals (NYSEMKT:ZOM), an under-the-radar play on the pet care space, is having an impressive time in the stock market today. In fact, one big catalyst has ZOM stock up more than 20% today.
So what exactly is Zomedica Pharmaceuticals? And what is that big catalyst? Starting with the first question, Zomedica Pharmaceuticals says that its goal is to improve the quality of veterinarian care by helping more veterinarians be successful. To do this, Zomedica works to provide veterinarian solutions that help with diagnostics.
Essentially, the easier it is for vets to figure out what is wrong with an animal, the easier it is to begin treatment.
With that in mind, Zomedica Pharmaceuticals shared exciting news on Friday. The company said that it expects to begin commercialization of its Truforma point-of-care diagnostics platform by March 2021. What does that mean? Well, Truforma uses bulk acoustic wave (BAW) technology to help detect thyroid and adrenal diseases in dogs and cats. Importantly, Zomedica says that this BAW tech helps improve accuracy, precision and timeliness. Instead of waiting for results, the Truforma platform can give patients insight during an initial appointment.
There are a few other things for investors to note here. To start, Zomedica believes that it is the first company to use BAW tech in this way. Along with this, the company has 70 issued or pending patents on Truforma, giving it a competitive edge in the pet care market. As investors consider the commercialization catalyst, they can also have some confidence that Zomedica will retain its dominance for some time.
Although the commercialization story is clearly an exciting one, there is another big catalyst lurking beneath the surface. Yes, that catalyst is the novel coronavirus pandemic.
As Americans spent more time than ever before at home, they increasingly turned to furry friends for comfort. Shelters emptied out. Dogs and cats flocked to new homes. And most importantly, spending on pet health and care products increased. In fact, unlike in previous economic crises, Americans spent more than before on their four-legged companions.
What does this mean for Zomedica Pharmaceuticals and ZOM stock? Well, there are now more households in America with dogs and cats. These households in turn are also spending more than before on taking care of their pets. All together, this means pet owners and vets will likely jump at the chance to provide better and more accurate diagnostics. For Zomedica, this should translate to steady demand for its Truforma point-of-care platform and any following diagnostic solutions.
On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Sarah Smith is a Web Content Producer for InvestorPlace.com.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Sarah Smith, InvestorPlace Web Content Producer
Watchdog group calls for SEC probe after Pfizer CEO dumps $5.6M in stock on day of vaccine news
A watchdog group called for the Securities and Exchange Commission to investigate stock sales by Pfizer chief executive Dr. Albert Bourla on the day the pharmaceutical giant announced that its coronavirus vaccine was more than 90% effective.
In a press release on Monday that made worldwide headlines, Pfizer claimed that study data indicates that the company’s experimental coronavirus vaccine is highly effective at preventing infection. Scientists warned that data from Pfizer’s clinical trial and specific details on the vaccine were not yet available. But President Trump and others touted the report, which lifted the company’s stock price by nearly 8%.
Bourla unloaded 132,506 shares of Pfizer stock at $41.94, near the company’s peak, for a total of nearly $5.6 million on the same day, SEC filings show. The transaction appeared to be Bourla’s first public sale of stock since 2016, though he has made non-market transactions, according to federal filings.
The stock sale raised questions after Bourla told CNN’s Sanjay Gupta that he learned of the positive trial results a day before they were publicly announced.
Amy Rose, the company’s vice president of global media relations, told Salon that the sale was prearranged through an SEC-compliant trading plan in August.
“The sale of these shares is part of Dr. Bourla’s personal financial planning and a pre-established (10b5-1) plan, which allows, under SEC rules, major shareholders and insiders of exchange-listed corporations to trade a predetermined number of shares at a predetermined time,” Rose said in an email. “Through our stock plan administrator, Dr. Bourla authorized the sale of these shares in February and renewed that authorization in August with the same price and volume terms. After being with the company for more than 25 years, Albert owns a substantial amount of Pfizer stock under our qualified and nonqualified savings plans. He now holds approximately nine times his salary in Pfizer stock after the sale this week.”
Sally Susman, the company’s executive vice president, also sold 43,662 shares for a total value of around $1.83 million under a pre-arranged plan, according to filings.
The company did not respond to questions about the impression conveyed to regulators or the public by these sales, or about whether it would freeze future stock sales by executives.
The prearranged plans are a common way to “shield corporate executives from allegations of illegal insider trading” but they have also become “increasingly controversial” given the “billions of dollars the government has promised Pfizer if its vaccine meets the approval of federal regulators,” NPR reported.
While such plans are intended only to be used when executives are not “in possession of inside information” that could affect a company’s stock price, the timing of Bourla’s plan raised questions because it was implemented on Aug. 19, a day before Pfizer announced that it was “on track to seek regulatory review” by October, NPR added.
Daniel Taylor, an insider trading expert at the Wharton School of the University of Pennsylvania, told NPR that the timing of the stock plan appeared “very suspicious.”
“It’s wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials,” he said.
A spokesperson for the company told NPR that it did not believe the Aug. 20 announcement had any material nonpublic information, adding that the company previously announced its plan to seek approval by October and was merely confirming the timeline.
Accountable Pharma, a progressive watchdog group, has called for Pfizer and other pharmaceutical companies to freeze the sale of stocks by executives “to prevent the kind of insider profiteering off of positive news that we’ve seen across the industry over the last few months.”
Eli Zupnick, a spokesman for the group, on Thursday called on the SEC to investigate the Pfizer sales.
“This appears to be another example of a shameless pump-and-dump and egregious pandemic profiteering that, if nothing else, is a terrible look for a drug industry that is desperately trying to rehabilitate its image,” he said in a statement to Salon. “We called on Pfizer to freeze all insider sales for exactly this reason, and now we’re calling on the SEC to investigate these trades to determine if these executives’ trading plans were inappropriately adjusted or if their options were exercised based on inside information.”
Zupnick added in a press release that Pfizer “should immediately release their study data for full independent review.”
“Given the billions of guaranteed taxpayer dollars that supported and incentivized the development of this vaccine, Pfizer must now explain how much they intend to profiteer off of this vaccine and what they intend to charge patients and the federal government beyond the initial doses,” he said.
Other pharmaceutical companies receiving funding from taxpayers have also come under fire for their executives’ stock trades. Executives at the pharmaceutical giant Moderna have sold off tens of millions in stock ahead of announcements about its vaccine development while receiving large contracts from the Trump administration.
“It’s troubling to me that the general counsel or the internal controls of these companies would consider it legitimate to adopt a 10b5-1 plan one day before a major vaccine announcement,” Taylor told NPR. “If this isn’t a wake-up call for the SEC and a wake-up call that we need to reform these 10b5-1 plans, I don’t know what it is.”
SEC Chairman Jay Clayton warned back in May that pharmaceutical firms should avoid these types of stock sales.
“We’ve said for a long time: In this volatile time, please practice good corporate hygiene,” he told CNBC. “Why would you want to even raise the question that you were doing something that was inappropriate?”
Trump bans US investment in Chinese military-linked firms
BEIJING (AP) – President Donald Trump has stepped up a conflict with China over security and technology by issuing an order barring Americans from investing in companies that U.S. officials say are owned or controlled by the Chinese military.
The impact of the order Thursday wasn’t immediately clear but it could add to pressure on companies including telecom equipment giant Huawei and video surveillance provider Hikvision that already face U.S. export bans and other sanctions.
It is Trump’s first major action toward China since he lost his reelection bid to challenger Joe Biden. Economists and political analysts have said even if Trump was defeated he was likely to launch more actions Beijing before he leaving office on Jan. 20.
Political analysts expect little change in policy under Biden due to widespread frustration with China’s trade and human rights records and accusations of spying and technology theft.
U.S. officials complain China’s ruling Communist Party takes advantage of access to American technology and investment to expand its military, already one of the world’s biggest and most heavily armed.
Thursday’s order complains the companies targeted “directly support” the Chinese military, intelligence and security apparatus. It said Beijing “exploits United States investors” to finance military development by selling securities in American and foreign financial markets.
The order bars American investors from conducting any transactions in publicly traded securities issued by any Chinese companies designated by the secretary of defense as being linked to the Communist Party’s military wing, the People’s Liberation Army.
The Pentagon earlier designated 31 companies as being owned or controlled by the Chinese military. Many are military contractors or state-owned companies such as phone carrier China Telecom Ltd. But the list also includes Huawei Technologies Ltd. and Hikvision Digital Technology Co., which say they are private and deny they are controlled by the military.
Hikvision criticized its inclusion in Thursday’s order as unjustified. The company said it is independent of the PLA and never has participated in research and development for “military applications.”
“As we have shown time and again, Hikvision is not a ‘Chinese military company,’” said a Hikvision statement. “These punitive actions against the company do not make America, or the world, any safer.”
Most of those companies have no shares traded in the United States but many sell stocks, bonds and other securities in markets outside mainland China that are accessible to American investors.
Sales made to divest securities of those companies will be allowed until one year from now on Nov. 11, 2021.
White House order: https://www.whitehouse.gov/presidential-actions/executive-order-addressing-threat-securities-investments-finance-communist-chinese-military-companies/
Copyright © 2020 The Washington Times, LLC.
Author: The Washington Times http://www.washingtontimes.com
Jeff Brown’s latest prediction on stock markets: The second wave
Stock markets are always unpredictable. You can lose money in split seconds or become a millionaire too.
However, Jeff Brown views the stock market differently, and losing is not his portion. He believes in seizing opportunities in current technologies and situations.
Jeff can predict potential brands to invest in for great profits in the future. During his latest prediction (the second wave), Brown feels the current market is not stable and poses a great risk in the near future.
At his Jeff Browns tech melt presentation, Jeff emphasized the prediction (the second wave), where he mentions about the stock market begins on the verge of a rupture. To resolve and get ways of unlocking the mystery, Brown urges investors and readers to check on his Brownstone Research near the Future Report.
Here you can learn what will happen in the future.
What is the second wave prediction all about?
Today, Jeff believes the market is on the verge of something none has witnessed in the past 20 years. The prediction targets large and popular tech stocks or brands.
Some have already reached dead ends, while others will crash hard. He estimates that 92 percent falls out. However, the investor says there are several tech industries. Which would support or grow your money during these hard times.
Jeff Brown believes in small sectors is overwhelming; according to Jeff, small industries are market resistant. In an example, he says the small markets can turn $5,000 to $1.5 million. The challenge is how you will know about the small stock markets. Again the answer is contained in the Brownstone research in the near future report.
The Covid-19 pandemic has affected major industries rendering them helpless and on the verge of diminishing. However, Jeff is optimistic about the situation and feels all is not lost.
Many companies have grown and developed in his view, and some with an expectation to thrive higher past the second wave. Jeff provides an example of a company expected to boom and thrives by up to 5,900 percent.
Hints about the potential company
What is ‘The near Future Report?’
This official newsletter was created as an investment advisory for readers and investors. It provides knowledge on investing in the current opportunities for a better future.
The advisory newsletter is published by Brownstone research. It aims at getting real-time trends which are profitable. He shares the knowledge by simplifying complex tech details to help subscribers gain instant profits from the market. Brown believes in small opportunities to win big.
In the newsletter, Jeff advises companies dealing with 5G, AI, and cloud computing.
What is included in the near future report?
Only members can enjoy the privilege of getting what on the newsletter. However, you get to learn about the following:
You must log in to post a comment.